SAN DIEGO, Sept. 20, 2019 /PRNewswire/ -- Shareholder
Rights Law Firm Johnson Fistel, LLP is investigating potential
claims against the following companies:
Trevena, Inc. (NASDAQ: TRVN) [click here to join this
action]
IVERIC bio, Inc. (NASDAQ: ISEE) [click here to join this
action]
Trevena, Inc.
Shareholder Rights Law Firm Johnson Fistel, LLP is investigating
potential claims against Trevena, Inc. (NASDAQ: TRVN) ('' Trevena
'').
Last year, a class action complaint was filed against
Trevena and certain of its officers and directors. The lawsuit
seeks to recover damages for Trevena investors under the federal
securities laws. The class period is from May 2, 2016 and October
9, 2018. The complaint alleges that defendants made
false and misleading statements during the Class Period and failed
to disclose material adverse facts to investors about the Company's
interactions with the U.S. Food and Drug Administration ("FDA")
concerning Oliceridine (TRV 130). Specifically, on
May 2, 2016, Trevena announced that
it had "reached general agreement" with the FDA on key elements of
its Phase 3 program for Oliceridine, and that it was "very pleased"
with the outcome of discussions with the FDA. In reality, the FDA
disagreed with Trevena on several key factors relating to whether
Oliceridine would ultimately be approved for commercial
distribution.
On October 9, 2018, it was
revealed that the FDA informed the Company in 2016
that it "did not agree with the proposed dosing in the Phase 3
studies," the proposed primary endpoint, or the "proposed
non-inferiority (NI) margin for comparing morphine to
Oliceridine."
If you are a long-term shareholder of Trevena continuously
holding shares before May 2,
2016, you may have standing to hold Trevena
harmless from the alleged harm caused by the officers and directors
of the Company by making them personally responsible. You may also
be able to assist in reforming the Company's corporate governance
to prevent future wrongdoing.
If you are interested in learning more about the
investigation are your legal rights and remedies, please contact
Jim Baker (jimb@johnsonfistel.com)
at 619-814-4471. If you email, please include your phone
number.
Additionally, you can [click here to join this action]. There
is no cost or obligation to you.
IVERIC bio, Inc.
Shareholder Rights Law Firm Johnson Fistel, LLP is investigating
potential claims against IVERIC bio, Inc. (NASDAQ: ISEE) ("IVERIC
") formerly called Ophthotech Corporation.
In 2017 a class action case filed against Ophthotech Corporation
and certain of its officers and directors seeking to pursue
remedies under sections 10(b) and 20(a) of the Exchange Act.
The class period is between March 2,
2015 and December 12,
2016. The case arises from Defendants' disseminating
materially false and misleading statements and/or concealing
material adverse facts regarding the Phase 2 and 3 trials of the
Company's most advanced product candidate Fovista. On
9/17/19 Judge Bernon S. Broderick denied the MTD.
If you are a long-term shareholder of
IVERIC continuously holding shares before
March 2, 2015, you may have
standing to hold IVERIC harmless from the alleged harm caused
by the officers and directors of the Company by making them
personally responsible. You may also be able to assist in reforming
the Company's corporate governance to prevent future
wrongdoing.
If you are interested in learning more about the
investigation are your legal rights and remedies, please contact
Jim Baker (jimb@johnsonfistel.com)
at 619-814-4471. If you email, please include your phone
number.
Additionally, you can [click here to join this action]. There
is no cost or obligation to you.
About Johnson Fistel,
LLP:
Johnson Fistel, LLP is a nationally
recognized shareholder rights law firm with offices in California, New
York, and Georgia. The firm
represents individual and institutional investors in shareholder
derivative and securities class action lawsuits. For more
information about the firm and its attorneys, please visit
http://www.johnsonfistel.com. Attorney advertising. Past results do
not guarantee future outcomes.
Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com
View original
content:http://www.prnewswire.com/news-releases/johnson-fistel-llp-announces-investigations-of-trevena-inc-and-iveric-bio-inc-long-term-investors-encouraged-to-contact-the-firm-300922355.html
SOURCE Johnson Fistel, LLP